dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Muu lepingAvalik

Leping

Sotsiaalministeerium · 10. juuni 2021
Viit
2-2.1/1464-1
Registreeritud
10. juuni 2021
Dokumendi liik
Muu leping
Funktsioon
2 Välisabi ja struktuuritoetuste rakendamine
Sari
2-2.1 Välisabi vahenditest rahastatavate projektide lepingud koos aktidega
Toimik
2-2.1
Vastutaja
Sille Pihlak (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Rahvatervise osakond)

Failid

  • 📎Best-ReMaP JA Consortium Agreement Final May 2021.pdf765 KB
  • 📎NIJZ kaaskiri.pdf24 KB

Sisu (failidest)

Best-ReMaP Joint Action Joint Action on Implementation of Validated Best Practices in Nutrition Consortium Agreement No. 631 - 81 / 2020 - 6 (323) May 2021 Ljubljana, 31st of May 2021 Best-ReMaP JA Consortium Agreement 31st of May 2021 Table of Contents Section 1: Definitions .............................................................................................................................. 6 Section 2: Purpose .................................................................................................................................. 9 Section 3: Entry into force, duration and termination .......................................................................... 9 Section 4: Responsibilities of beneficiaries.......................................................................................... 10 Section 5: Liability towards each other................................................................................................ 12 Section 6: Governance structure .......................................................................................................... 13 Section 7: Financial provisions ............................................................................................................. 18 Section 8: Results .................................................................................................................................. 20 Section 9: Access Rights ........................................................................................................................ 23 Section 11: Non-disclosure of information .......................................................................................... 26 Section 12: Miscellaneous .................................................................................................................... 28 Section 13: Signatures .......................................................................................................................... 29 Attachment 1: Background included ................................................................................................... 54 Attachment 2: Accession document .................................................................................................... 56 2 Best-ReMaP JA Consortium Agreement 31st of May 2021 Consortium Agreement This Consortium Agreement is based upon the Grant Agreement between the Agency1, acting under powers delegated by the Commission of the European Communities (“EC”) and the beneficiaries of this Grant Agreement (Grant Agreement Number – 951202) concerning the action “Joint Action on Implementation of Validated Best Practices in Nutrition” hereinafter referred to as “Joint Action” or “JA” or “Best-ReMaP JA” laying down the rules for the participation and dissemination in the 3rd Health Programme (2014- 2020)” (hereinafter referred to as “the Rules”), the EU Action Plan on childhood obesity 2014 – 2020 of 24 February 2014 and the European Commission Multi-beneficiary General Model Grant Agreement and its Annexes, and is effective as of 1 October 2020 hereinafter referred to as “the starting date of Joint Action” and the “Effective Date” BY AND AMONG: 1. The Coordinator, NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ) Trubarjeva cesta 2, 1000 Ljubljana, Slovenia, VAT number: SI44724535, represented for the purposes of signing the Agreement by Director Milan Krek and the following other beneficiaries, if they sign their “Accession Form” (see Annex 3 and Article 40 of the Grant Agreement): 2. BUNDESMINISTERIUM FUER SOZIALES, GESUNDHEIT, PFLEGE UND KONSUMENTENSCHUTZ (BMSGPK) Radetzkystrasse 2 Wien 1030, Austria ATU38680502 3. SCIENSANO (SCIENSANO) Juliette Wytsmanstraat 14 Elsene 1050, Belgium VAT number: BE069387830 4. THE MINISTRY OF CIVIL AFFAIRS (MCA) Trg Bosne i Hercegovine 1 Sarajevo 71000, Bosnia and Herzegovina 1 For the purpose of this Consortium Agreement the term “the Agency” will collectively be used to refer to Consumers, Health, Agriculture and Food Executive Agency (CHAFEA), with whom the beneficiaries have entered into the Grant Agreement Nr. 951202 and European Health and Digital Executive Agency (HaDEA) or other Agency, acting as a Funding Authority, under powers delegated by the Commission of the European Communities (“EC”). 3 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 5. NATSIONALEN CENTAR PO OBSHTESTVENO ZDRAVE I ANALIZI (NCPHA) ACAD IVAN GESHOV BLVD 15, Sofia 1431, Bulgaria VAT number: BG176094665 6. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH) ROCKEFELLEROVA 7 Zagreb 10000, Croatia VAT number: HR75297532041 7. Ministry of Health of the Republic of Cyprus (MoH CY) 1 Prodromou Street & 17 Chilonos Street Nicosia 1448, Cyprus 8. FODEVARESTYRELSEN (DVFA) STATIONSPARKEN 31 GLOSTRUP 2600, Denmark VAT number: DK62534516 9. SOTSIAALMINISTEERIUM (MoSA) Suur-Ameerika 1 Tallinn 10122, Estonia VAT number: EE100535271 10. TERVEYDEN JA HYVINVOINNIN LAITOS (THL) MANNERHEIMINTIE 166 Helsinki 00271, Finland VAT number: FI22295006 11. AGENCE NATIONALE DE SECURITE SANITAIRE DE L ALIMENTATION DE L ENVIRONNEMENT ET DU TRAVAIL (ANSES) 14 RUE PIERRE ET MARIE CURIE MAISONS ALFORT 94700, France VAT number: FR54130012024 12. MAX RUBNER INSTITUT BUNDESFORSCHUNGSINSTITUT FUR ERNAEHRUNG UND LEBENSMITTEL (MRI) HAID UND NEU STRASSE 9 KARLSRUHE 76131, Germany VAT number: DE811393840 13. INSTITOUTON YGEIAS TOU PAIDIOU (ICH) Thivon & Papadiamantopoulou 1, ATHENS 11527, Greece VAT number: EL090073098 4 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 14. SEMMELWEIS EGYETEM (SU) ULLOI UT 26 BUDAPEST 1085, Hungary VAT number: HU15329808 Responsible organisational unit: Health Services Management Training Centre Represented by: Dr. Béla Merkely, Rector and Dr. Lívia Pavlik, Chancellor jointly 15. DEPARTMENT OF HEALTH (DoH) Block 1, Miesian Plaza, 50-58 Lower Baggot Street Dublin D02 XW14, Ireland 16. ISTITUTO SUPERIORE DI SANITA (ISS) VIALE REGINA ELENA 299, ROMA 00161, Italy VAT number: IT03657731000 17. SLIMIBU PROFILAKSES UN KONTROLES CENTRS (CDPC) Duntes 22, K-5 Riga LV1005, Latvia VAT number: 90009756700 18. LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (LR SAM) VILNIAUS G 33 VILNIUS LT 01506, Lithuania 19. Ministry for Health - Government of Malta (MFH) Palazzo Castellania, Merchants Street 15 Valletta VLT 200, Malta VAT number: MT12979127 20. The State of the Netherlands, represented by its Minister of Health, Welfare and Sport, on behalf of the Minister represented by Prof. dr. ir. J. Brug, Director-General of the National Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en Milieu) (RIVM) Antonie van Leeuwenhoeklaan 9 3721 MA Bilthoven, the Netherlands, VAT number: NL821772302B01 (“RIVM”) 21. SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH (SUM) UL. PONIATOWSKIEGO 15, KATOWICE 40 055, Poland VAT number: PL6340005301 22. MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (DGS) Av. João Crisóstomo, 9 1049-062 Lisboa, Portugal 23. INSTITUTUL NATIONAL DE SANATATE PUBLICA (NIPH) STR DR LEONTE 1-3 SECTOR 5 BUCURESTI 050463, Romania 5 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 24. INSTITUT ZA ZASTITU ZDRAVLJA SRBIJEDR MILAN JOVANOVIC BATUT (IPHS) DR SUBOTICA STREET 5 Beograd 11000, Serbia VAT number: RS102000930 hereinafter, jointly or individually, referred to as “beneficiaries” or ”beneficiary”, relating to the Joint Action entitled “Joint Action on Implementation of Validated Best Practices in Nutrition ”, in short Best-ReMaP JA. Best-ReMaP JA shall run for 36 months from October 1, 2020 hereinafter referred to as “the starting date of Joint Action” and the “Effective Date”. WHEREAS: The beneficiaries, having considerable experience in the field concerned, have submitted a proposal for the Project to the Funding Authority as part of the 3rd EU Health Programme (2014-2020). The beneficiaries wish to specify or supplement binding commitments among themselves in addition to the provisions of the Grant Agreement number 951202 signed by the beneficiaries and the EC (hereinafter “Grant Agreement” and “GA”). Best ReMaP JA is funded by the European Union’s Health Programme (2014-2020). The beneficiaries are aware that this Consortium Agreement is based upon the DESCA model consortium agreement and modified according to the Grant Agreement. NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS: Section 1: Definitions 1.1 Definitions Words beginning with a capital letter shall have the meaning defined either herein or in the Rules or in the Grant Agreement including its Annexes. 1.2 Additional Definitions “Access Rights” Access rights means rights to use Results or Background under the terms and conditions laid down in accordance with this Consortium agreement. “Affiliated entities” See Grant Agreement Article 11.1, and Article 187, of the Regulation (EU, Euratom) 2018/1046 of the European Parliament and of the Council of 18 July 2018 on the financial rules applicable to the general budget of the Union (herein after referred to as the Regulation (EU, Euratom) 2018/1046) – entities affiliated to the beneficiary are: 6 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 (a) entities that form a ‘sole beneficiary’ (i.e. where an entity is formed of several entities that satisfy the criteria for being awarded a grant, including where the entity is specifically established for the purpose of implementing an action to be financed by a grant); (b) entities that satisfy the eligibility criteria and that do not fall within one of the situations referred to in Articles 136(1) and 141(1) of the Regulation (EU, Euratom) 2018/1046 and that have a link with the beneficiary, in particular a legal or capital link, which is neither limited to the action nor established for the sole purpose of its implementation. “Associated Partner” An Associated Partner has a contractual relationship with the Agency and appears on the Grant Agreement, even though mandating the Coordinator to sign it. “Background” Background means any data, know-how or information — whatever its form or nature (tangible or intangible), including any rights such as intellectual property rights — that: (a) is held by the beneficiaries before they acceded to the Agreement, and (b) is needed to implement the action or exploit the results. (Background corresponds to pre-existing rights in Grant Agreement article 19.1) Background used within the scope of the Joint Action is defined in Attachment 1. “Beneficiary” Beneficiary or beneficiaries means a beneficiary or the beneficiaries to this Consortium Agreement also identified as the beneficiaries to the Grant Agreement. “Collaborating Partner” A Collaborating Partner provides added value to the Joint Action and participates in the Joint Action together with the Coordinator and Associated Partners, but has no contractual relationship with the Agency. A Collaborating Partner carries no legal link to the JA and does not receive any EU funding. “Competent Authority” Competent Authority means the central authority nominated by the Member State which has signed the Grant Agreement as beneficiary of EU Funding. “Consortium Body” Consortium Body means any structure of the Consortium, i.e. either General Assembly or Steering Committee. “Data” Data means any and all data which is part of a beneficiary’s Background included in the Joint Action or which is generated under the Joint Action as “results”, including, as the case may be, personal data as defined and protected under the European or national applicable legislation(s). 7 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 “Dissemination” Dissemination means the public disclosure of the results by any appropriate means (other than resulting from protecting or exploiting the results), including by scientific publications in any medium. “Exploitation” Exploitation means the use of results in further research activities other than those covered by the Joint Action concerned, or in developing, creating and marketing a product or process, or in creating and providing a service, or standardisation activities. “Fair and reasonable conditions” Fair and reasonable conditions means appropriate conditions, including possible financial terms or royalty-free conditions, taking into account the specific circumstances of the request for access, for example the actual or potential value of the results or background to which access is requested and/or the scope, duration or other characteristics of the exploitation envisaged. “Foreground” means the results, including namely, but not exclusively, all documents, recommendations, guidelines, information, materials and knowledge, generated within the project or as a result of it. It includes all intellectual property rights (such as, but not limited to, the rights resulting from copyright protection, related rights, design rights, patent rights) and knowhow. “Funding Authority” Funding Authority means the body awarding the grant for the Joint Action. “Data Protection Laws” Data Protection Laws means all applicable legislation concerning the protection of personal data, including the Regulation (EU) 2016/679 Of The European Parliament And Of The Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (hereinafter referred to as General Data Protection Regulation or ”GDPR”), any other data protection legislation applicable to the Joint Action, as well as the binding orders of data protection authorities. “Defaulting beneficiary” Defaulting beneficiary means a beneficiary which the majority of the Steering Committee has identified to be in breach of this Consortium Agreement and/or the Grant Agreement as specified in Section 4.4 of this Consortium Agreement. “Needed” For the implementation of the Joint Action: Access Rights are Needed if, without the grant of such Access Rights, carrying out the tasks assigned to the recipient beneficiary would be impossible, significantly delayed, or require significant additional financial or human resources. For exploitation of own Results: Access Rights are needed if, without the grant of such Access Rights, the Exploitation of own Results would be technically or legally impossible. 8 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 “Results” Results means any tangible or intangible output of the Joint Action, such as data, knowledge or information, that is generated in the Joint Action, whatever its form or nature, whether or not it can be protected, as well as any rights attached to it, including intellectual property rights. Section 2: Purpose The purpose of this Consortium Agreement is to specify with respect to the Joint Action the relationship among the beneficiaries, in particular concerning the organisation of the work between the beneficiaries, the management of the Joint Action and the rights and obligations of the beneficiaries concerning inter alia liability, Access Rights and dispute resolution. Section 3: Entry into force, duration and termination 3.1 Entry into force An entity becomes a beneficiary to this Consortium Agreement upon signature of this Consortium Agreement by a duly authorised representative. This Consortium Agreement shall come into force at the date of its signature by the beneficiaries and shall have retroactive effect as of 1 October 2020. An additional entity becomes a beneficiary to the Consortium Agreement upon signature of the accession document (Attachment 2) by the new beneficiary and the Coordinator. Such accession shall have effect from the date identified in the accession document. 3.2 Duration and termination This Consortium Agreement shall continue in full force and effect until complete fulfilment of all obligations undertaken by the beneficiaries under the Grant Agreement and under this Consortium Agreement. However, this Consortium Agreement or the participation of one or more beneficiaries to it may be terminated in accordance with the terms of this Consortium Agreement. If the Grant Agreement - is not signed by the Funding Authority or a beneficiary, or - is terminated, - or if a beneficiary's participation in the Grant Agreement is terminated, this Consortium Agreement shall automatically terminate in respect of the affected beneficiary/ies, subject to the provisions surviving the expiration or termination under Section 3.3 of this Consortium Agreement. 9 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 3.3 Survival of rights and obligations The provisions relating to Access Rights, Dissemination and Confidentiality, for the time period mentioned therein, as well as for liability, applicable law and settlement of disputes shall survive the expiration or termination of this Consortium Agreement. Termination shall not affect any rights or obligations of a beneficiary leaving the Consortium incurred prior to the date of termination, unless otherwise agreed between the Steering Committee and the leaving beneficiary. This includes the obligation to provide all input, deliverables and documents for the period of its participation. Section 4: Responsibilities of beneficiaries 4.1 General principles As health enablers, beneficiaries hereby undertake to advocate for the development of good practices in nutrition, with due respect and in accordance with public health policies. Within the Best-ReMaP JA any cooperation and communication with stakeholders should be taken under the public health driven agenda, recognizing transparency as one of the general principles. Each beneficiary undertakes to take part in the efficient implementation of the Best-ReMaP JA, and to cooperate, perform and fulfil, promptly and on time, all of its obligations under the Grant Agreement and this Consortium Agreement as may be reasonably required from it and in a manner of good faith as prescribed by the applicable EU law, supplemented if necessary by the law of Belgium. Each beneficiary undertakes to notify promptly the Coordinator about any significant information, fact, problem or delay likely to affect the Joint Action. Each beneficiary shall promptly provide all information reasonably required by a Consortium Body or by the Coordinator to carry out its tasks. Each beneficiary shall take reasonable measures to ensure the accuracy of any information or materials it supplies to the other beneficiaries. Each beneficiary shall act in accordance with the requirements of the Data Protection Laws. Each beneficiary is responsible for ensuring that the processing of the data carried out by it is in accordance with the Data Protection Laws and in accordance with Section 10 of this Agreement. 4.2 Beneficiaries Beneficiaries are the competent authorities nominated by the participating countries. They must: - Keep information stored in the Participant Portal Beneficiary Register (in the electronic exchange system) up to date (see Article 12 of the Grant Agreement); - Inform the Coordinator immediately of any events or circumstances likely to affect significantly or delay the implementation of the action (see Article 12 of the Grant Agreement); 10 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 - Discuss any proposed activities which are not part of the Grant Agreement and annual work plans, i.e. need an amendment, first with the WP lead, who can propose the changes to the Coordinator. - Submit to the Coordinator in good time: o Individual financial statements for itself and its affiliated entities (if applicable) and, if required, certificates on the financial statements (see Article 15 of the Grant Agreement); o The data needed to draw up all requested reports under Article 15 of the Grant Agreement; o If applicable, ethics committee opinions and notifications or authorisations for activities raising ethical issues; o Submit financial progress reports to the Coordinator in accordance with Section 7; o Any other document(s) or information required by the Agency or the Commission under the Grant Agreement, unless the Grant Agreement requires the beneficiary to submit this information directly to the Agency or the Commission. In addition, work package (WP) leaders are obliged to: - Submit technical reports to the Coordinator in accordance with Section 7; - Monitor the effective and efficient implementation of the WP; - Discuss any proposed activities which are not part of the Grant Agreement and annual work plans, i.e. need an amendment, with the Coordinator. 4.3 Involvement of third parties A beneficiary that enters into a subcontract or otherwise involves third parties (including but not limited to affiliated entities defined in the Grant Agreement Article 11) in the Joint Action remains responsible for carrying out its relevant part of the Joint Action and for such third party’s compliance with the provisions of the Grant Agreement. It has to ensure that the involvement of third parties does not affect the rights and obligations of the beneficiaries under this Consortium Agreement and the Grant Agreement. In addition, affiliated entities are obliged to: - Keep information stored in the Participant Portal Beneficiary Register (in the electronic exchange system) up to date (see Article 12 of the Grant Agreement). 4.4 Breach In the event that the Steering Committee identifies a breach by a beneficiary of its obligations under this Consortium Agreement or the Grant Agreement (e.g. improper implementation of the Joint Action), the Coordinator or, if the Coordinator is in breach of its obligations, the beneficiary appointed by the Steering Committee, will give formal notice to such beneficiary requiring that such breach will be remedied within 30 calendar days from the date of receipt of the written notice by the beneficiary. 11 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 If such breach is substantial and is not remedied within that period or is not capable of remedy, the Steering Committee may decide to declare the beneficiary to be a Defaulting beneficiary and to decide on the consequences thereof which may include termination of its participation. 4.5 Compliance Each beneficiary shall ensure that its work on the Joint Action complies fully with all applicable local, government and international laws, regulations and guidelines which are effective during the period of the Grant Agreement, including those governing health and safety and data protection. Section 5: Liability towards each other 5.1 No warranties In respect of any information or materials, incl. Results (Grant Agreement Article 19) and Background, supplied by one beneficiary to another under the Joint Action, no warranty or representation of any kind is made, given or implied as to the sufficiency or fitness for purpose nor as to the absence of any infringement of any proprietary rights of third parties. This does not apply to Subsection 9.2.1. Therefore, - the recipient beneficiary shall in all cases be entirely and solely liable for the use to which it puts such information and materials, and - no beneficiary granting Access Rights shall be liable in case of infringement of proprietary rights of a third party resulting from any other beneficiary (or its affiliated entities) exercising its Access Rights. 5.2 Limitations of contractual liability No beneficiary shall be responsible to any other beneficiary for any indirect or consequential loss or similar damage such as, but not limited to, loss of profit, loss of revenue or loss of contracts, provided such damage was not caused by a wilful act or gross negligence or by a breach of confidentiality. For any remaining contractual liability, a beneficiary’s aggregate liability towards the other beneficiaries collectively shall be limited to once the beneficiary’s share of the total costs of the Joint Action as identified in Annex 2 of the Grant Agreement provided such damage was not caused by a wilful act or gross negligence. The terms of this Consortium Agreement shall not be construed to amend or limit any beneficiary’s statutory liability. 5.3 Damage caused to third parties 12 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Each beneficiary shall be solely liable for any loss, damage or injury to third parties resulting from the performance of the said beneficiary’s obligations by it or on its behalf under this Consortium Agreement or from its use of Results or Background. 5.4 Force Majeure No beneficiary shall be considered to be in breach of this Consortium Agreement if it is prevented from fulfilling its obligations under the Consortium Agreement by Force Majeure (as defined in Article 35 of the Grant Agreement). Each beneficiary will notify the competent Consortium Bodies of any Force Majeure without undue delay. If the consequences of Force Majeure for the Joint Action are not overcome within 6 weeks after such notification, the transfer of tasks - if any - shall be decided by the Steering Committee. Section 6: Governance structure 6.1 General structure The organisational structure of the Consortium shall comprise the following Consortium Bodies: Project Management Team (PMT) as an internal working group of administrative, financial and scientific support within NIJZ. Steering Committee (SC) is the main oversight committee of the Joint Action. General Assembly (GA) meetings consisting of representatives of all Associated Partners and the PMT, with Collaborating Partners and possibly other related projects and initiatives invited. The meetings will be held to discuss progress on JA objectives with the entire Associated Partner consortium. Policy decision making forum (PDMF) as a policy advisory board to the JA, will be informed on the JA progress and proposals of the institutionalised / legislative solutions and asked for comments/feedback with regard to the policy implementation options for the JA Best-ReMaP outputs. Coordinator is the legal entity acting as the intermediary between the Parties and the Funding Authority. The Coordinator shall, in addition to its responsibilities as a Party, perform the tasks assigned to it as described in the Grant Agreement and this Consortium Agreement. 6.2 General operational procedures for all Consortium Bodies 6.2.1 Representation in meetings Any beneficiary which is a member of a Consortium Body (hereinafter referred to as "Member"): - should be represented at any meeting of such Consortium Body; - may appoint a substitute or a proxy to attend and vote at any meeting; - and shall participate in a cooperative manner in the meetings. 13 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 6.2.2 Preparation and organisation of meetings The Coordinator shall convene meetings of all Consortium Bodies. Ordinary meeting Project Management Team At least once a week Work Package Leaders Monthly meetings with PMT Steering Committee At least six times during the course of the JA General Assembly Four GA meetings over the course of the JA Policy Decision Making Forum Three PDMF meetings are planned within the JA The Coordinator shall give notice in writing of a meeting to each Member of that Consortium Body as soon as possible and no later than the minimum number of days preceding the meeting as indicated below. Ordinary meeting Steering Committee 21 calendar days General Assembly 30 calendar days Policy Decision Making Forum 30 calendar days Any decision may also be taken without a meeting if the Coordinator circulates to all Members of the Consortium Body a written document (e-mail) which is then agreed by all Members of the Consortium Body. Such document shall include an appropriate deadline (minimum 7 calendar days) for responses. Non-response within the deadline and after sending a written reminder including a grace period (minimum 7 calendar days) shall be considered as agreement provided that the document has been sent to an address given to the Coordinator by each Member. The decisions will be binding after the Coordinator sends written notification of acceptance to all Members of the Consortium Body. Meetings of each Consortium Body may also be held by teleconference or other telecommunication means. Decisions will only be binding once the relevant part of the Minutes has been accepted according to Section 6.2.4. 6.2.3 Voting rules Consortium bodies shall aim to achieve decisions through a consensus approach. This approach entails discussion that aims to achieve consensus among members in order to promptly resolve the issues at hand. Even if a unanimous decision cannot be reached, a group discussion where everyone's opinions 14 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 are heard and regarded shall take place, resulting in establishing the best solution that the Consortium Body can achieve at a given time. 6.2.4 Minutes of meetings 6.2.4.1 The Coordinator shall produce written minutes of each meeting which shall be the formal record of all decisions taken. The Coordinator shall send the draft minutes to all Members within 21 calendar days of the meeting. The previous paragraph does not apply for the PDMF Meeting minutes. 6.2.4.2 The minutes shall be considered as accepted if, within 10 calendar days from sending, no Member has sent an objection in writing to the Coordinator with respect to the accuracy of the draft of the minutes. 6.2.4.3 The Coordinator shall safeguard the accepted minutes and send them to all the Members of the Consortium Body. 6.3 Specific operational procedures for the Consortium Bodies 6.3.1 Project Management Team (PMT) In addition to the rules in Section 6.2, the following rules apply: 6.3.1.1 Members The Project Management Team shall consist of the Scientific Coordinator, Project Manager, Financial Officer, Secretariat, Communications Officer, Legal Officer and researchers. 6.3.1.2 Tasks - The Project Management Team shall discuss and resolve daily management issues. - It shall act as liaison between all Associated Partners and the Agency. - The Project Management Team shall communicate with the WP Leaders, Associated and Collaborating Partners via a variety of methods. These include, but are not limited to: e-mail, telephone, tele-, web- and videoconference, face to face meetings. Emphasis will be put on regular bilateral web-conferences between the PMT and individual WPs, as well as online SC meetings. Key documents to be produced include: Project Policy, Financial Policy, Consortium Agreement, Interim and Final Reports. 6.3.2 Steering Committee (SC) In addition to the rules described in Section 6.2, the following rules apply: 15 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 6.3.2.1 Members The Steering Committee shall consist of the Work Package leaders, Project Management Team and representatives of the European Commission (hereinafter SC Members). The SC will be supported by academic experts from relevant scientific fields, such as agri-food chain, national level public food procurement, experts with specific knowledge on child legislation, as well as experts on health inequalities. The Coordinator shall chair all meetings of the Steering Committee. 6.3.2.2 Tasks - The Steering Committee shall monitor the effective and efficient implementation of the Joint Action and accept action plans on specific issues, where needed; - It shall discuss all issues, which bear on the implementation of the JA, both in the realm of scientific issues as well as administrative issues; - The Steering Committee will be regularly updated and consulted on: the progress of the JA and its WPs, activities of the coordinator at policy level, synergies and activities carried out by the horizontal WPs 1-4, timely preparation of interim and final reports, as well as regular updating on financial expenditure of the JA by WPs and individual partners, where problematic. 6.3.3 General Assembly (GA) In addition to the rules described in Section 6.2, the following rules apply: 6.3.3.1 Members General Assembly (GA) meetings consisting of representatives of all Associated Partners and the PMT, with Collaborating Partners and possibly other related projects and initiatives invited. The Coordinator shall chair all meetings of the General Assembly. 6.3.3.2 Tasks - General Assembly meetings will be held to discuss progress on Joint Action objectives with the entire Associated Partner consortium. 6.3.4 Policy decision making forum (PDMF) In addition to the rules described in Section 6.2, the following rules apply: 6.3.4.1 Members Policy decision making forum (PDMF) shall consist of the representatives of DG Santé, DG-Agri, DG Connect, DG Research, DG JRC, other relevant DGs, representatives of EU Agencies and bodies such as EFSA and ERGA, representatives of the EU Parliament, representatives of the current Presidencies, WP Leaders. The Coordinator shall chair all meetings of the PDMF. 16 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 6.3.4.2 Tasks - The Policy decision making forum shall act in synergy with the horizontal Work Packages and particularly Work Packages 4-7. - Depending on the nature of the proposals, meeting documents and agenda topics, the Policy decision making forum PDMF will be asked to provide critical feedback on the feasibility of implementation at national and EU level, with a view to the achievement of the Joint Action outcome indicators as set out in the Grant Agreement. - Policy briefs with EU stakeholders will be produced in order to capitalise on the work of the PDMF and expedite implementation, this will be done in conjunction with WP 2 and 4 (that will be responsible for Policy briefs production). - WP 1 will be responsible for coordinating and preparing the meeting documents for the PDMF. 6.4 Coordinator 6.4.1 The Coordinator shall be the intermediary between the beneficiaries and the Funding Authority and shall perform all tasks assigned to it as described in the Grant Agreement and in this Consortium Agreement. 6.4.2 In particular, the Coordinator shall: - Monitor that the action is implemented properly (see Article 7 of the Grant Agreement); - Act as the intermediary for all communications between the beneficiaries and the Agency (in particular, providing the Agency with the information described in Article 12 of the Grant Agreement), unless the GA specifies otherwise; - Request and review any documents or information required by the Agency and verify their completeness and correctness before passing them on to the Agency; - Submit the deliverables and reports to the Agency (see Articles 14 and 15 of the Grant Agreement); - Ensure that all payments are made to the other beneficiaries without unjustified delay (see Article 16 of the Grant Agreement); - Inform the Agency of the amounts paid to each beneficiary, when required in the Grant Agreement (see Articles 28 and 34) or requested by the Agency, or in the context of ex post Audits. 6.4.3 The Coordinator shall not be entitled to act or to make legally binding declarations on behalf of any other beneficiary or of the consortium, unless explicitly stated otherwise in the Grant Agreement or this Consortium Agreement, or unless it is expressly agreed in written form. 17 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 6.4.4 The Coordinator shall not enlarge its role beyond the tasks specified in this Consortium Agreement and in the Grant Agreement. Section 7: Financial provisions 7.1 General Principles 7.1.1 Justifying Costs In accordance with its own usual accounting and management principles and practices, each beneficiary shall be solely responsible for justifying its costs with respect to the Joint Action towards the Coordinator and/or Funding Authority. Each beneficiary will establish the necessary legal, administrative and/or operational arrangements with their affiliated entities to ensure the correct justification of the costs incurred. The Coordinator is an intermediary between the beneficiaries and the Funding Authority. The Coordinator is responsible for passing on to beneficiaries any claims the Funding Authority might have in respect of the Grant Agreement, and supplying all the required documents and information to the Funding Authority. Beneficiaries shall certify that the information provided in their financial reports to the Funding Authority (via the Coordinator) is full, reliable and true. They shall also certify that the costs incurred are eligible in accordance with Article 6 of the Grant Agreement. There will be 6 internal interim financial reports, each covering a period of 6 months. Internal interim financial report should be sent to the Coordinator by each beneficiary within 1 month after the related reporting period. Nr. of report Reporting period Due date M1-M6 M8 Report 1 (October 2020 – March 2021) (May 2021) M7-M12 M13 Report 2 (April 2021 – September 2021) (October 2021) M13-M18 M19 Report 3 (October 2021 – March 2022) (April 2022) M19-M24 M25 Report 4 (April 2022 – September 2022) (October 2022) M25-M30 M31 Report 5 (October 2022 – March 2023) (April 2023) M19-M36 M37 Report 6 (April 2023 – September 2023) (October 2023) 18 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Financial and technical reporting to the Funding Authority consists of two reports: Report Reporting period M1 – M18 (October 2020 – March 2022) INTERIM REPORT FINAL REPORT M19 – M36 (April 2022 – September 2023) All beneficiaries should submit all reports according to the instructions set in the Grant Agreement. The Coordinator must review and explicitly approve the Interim and Final reports before submission to Funding Authority. Interim and Final Reports are submitted to Funding Authority by the Coordinator within 60 days following the end of each reporting period (M1-18 and M19-36). 7.1.2 Funding Principles A beneficiary which spends less than its allocated share of the budget as set out in the Grant Agreement will be funded in accordance with its actual duly justified eligible costs only. A beneficiary that spends more than its allocated share of the budget as set out in the Grant Agreement will be funded only in respect of duly justified eligible costs up to an amount not exceeding that share, unless otherwise agreed with the Funding Authority. 7.1.3 Financial Consequences of the termination of the participation of a beneficiary A beneficiary leaving the consortium shall refund all payments it has received except for the work contribution approved by the Funding Authority. Furthermore, a Defaulting beneficiary shall bear any reasonable and justifiable additional costs occurring to the other beneficiaries in order to perform its and their tasks. 7.2 Payments 7.2.1 Payment schedule The payment schedule, which contains the transfer of pre-financing, interim and final payments to beneficiaries, will be handled according to the Article 16 of the Grant Agreement. Funding of costs included in the Grant Agreement will be paid to beneficiaries after receipt from the Funding Authority in separate instalments as agreed below: 100% on receipt of Advance Payment (pre-payment) Interim payment reimburses the eligible costs incurred for the implementation of the action during the corresponding reporting period. Limit to 90% of the maximum grant amount. Payment of the balance, on the basis of the request for payment of the balance 19 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Funding for costs accepted by the Funding Authority will be paid to the beneficiary concerned. The Coordinator is entitled to withhold any payments due to a beneficiary identified by the Steering Committee to be in breach of its obligations under this Consortium Agreement or the Grant Agreement. The Coordinator is equally entitled to withhold payments to a beneficiary, in accordance with circumstances, described in Article 5.3.4, 5.4, 27.2 and 28 of the Grant Agreement or when this is suggested by or agreed with the Funding Authority. The Coordinator will inform each such beneficiary about the reasons for withholding funds and release terms. The Coordinator is entitled to recover any payments already paid to a Defaulting beneficiary. Each beneficiary’s responsibility in case of recovery of undue amounts is limited to its own debts. Undue amounts paid by Funding Authority for costs declared by an affiliated entity will be considered as amounts unduly paid to the beneficiary concerned. The Coordinator will inform each such beneficiary about the procedure of the recovery of the amounts:  with detailed information about the reasons for the recovery and the amount due;  with a debit note with the terms and the date of the payment. 7.2.2 Payments from Funding Authority to beneficiaries are the exclusive tasks of the Coordinator The financial contribution of the Joint Action should be distributed by the Coordinator to beneficiaries according to: • the approval of reports by Funding Authority; and • the provisions of payments in the Grant Agreement. The Coordinator will transfer the financial contributions to the beneficiaries, including the financial contributions of their affiliated entities, within 30 calendar days from receipt of transfer. Beneficiaries should transfer received financial contributions for their affiliated entities without unjustified delay. Beneficiaries should provide the Coordinator with updated financial information on bank transfer details in a timely manner. Section 8: Results 8.1 Ownership of results Unless stipulated otherwise in the Grant Agreement, ownership of the results of the JA, including both intellectual property rights and of the reports and documents relating to it, shall be vested in the beneficiaries. Foreground resulting from the JA shall be owned by the beneficiary generating it. When Foreground is generated jointly, it shall be jointly owned, unless the beneficiaries in question agree on a different solution. 20 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Unless otherwise agreed: - each of the joint owners shall be entitled to use their jointly owned Results for non-commercial research activities on a royalty-free basis, and without requiring the prior consent of the other joint owner(s), and - each of the joint owners shall be entitled to otherwise Exploit the jointly owned Results and to grant non-exclusive licenses to third parties (without any right to sub-license), if the other joint owners are given: a) at least 45 calendar days advance notice with a right for the other joint owners to object hereto at the latest 15 days after receipt of such notice; and b) if no objection is made within the time limit stated above, the permission is given by the other joint owners who each shall receive Fair and Reasonable compensation taking into account each joint owner's relative contribution to the jointly owned Results. However, the joint owners shall, as soon as possible after the creation of the joint Results enter into a Joint Ownership Management Agreement to agree on all protection measures, ownership percentages and the division of related costs in advance. 8.2 Transfer of Results 8.2.1 Each beneficiary may transfer ownership of its own Results. It must however ensure that its obligation under the Grant Agreement and this Consortium Agreement also apply to the new owner and that this owner has the obligation to pass them on in any subsequent transfer. 8.2.2 Unless otherwise agreed in writing for specifically-identified Third Parties or unless impossible under applicable EU and national laws on mergers and acquisitions, a Party that intends to transfer ownership of results must give at least 45 days advance notice (or less if agreed in writing) to the other beneficiaries that still have (or still may request) access rights to the results. This notification must include sufficient information on the new owner to enable any beneficiary concerned to assess the effects on its access rights. Unless otherwise agreed in writing for specifically-identified Third Parties, any beneficiary may object within 30 days of receiving notification (or less if agreed in writing), if it can show that the transfer would adversely affect its Access rights. In this case, the transfer may not take place until agreement has been reached between the beneficiaries concerned. 8.2.3 The obligations above apply only for as long as other beneficiaries still have - or still may request - Access Rights to the Results. 8.3 Dissemination 8.3.1 For the avoidance of doubt, nothing in this Section 8.4 has impact on the confidentiality obligations set out in Section 10. 8.3.2 Dissemination of own Results The beneficiaries acknowledge their common interest in publishing Results to obtain recognition within the scientific community and to advance the state of scientific knowledge in their scientific field. 21 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 It is contemplated that the Results will jointly be published whenever applicable, notably in the respect of the fact that one such Result is jointly-owned; however, the beneficiaries each separately reserve the right to publish their own Results and Background. Authorship on joint publications will be based on academic standards and customs. The beneficiary(ies) wishing to make a publication or communication will provide a copy of such proposed abstract or publication manuscript (and a reasonably detailed description of any such oral presentation or other public disclosure) to all the beneficiaries concerned via the Coordinator, at least fifteen (15) days prior to any submission of publication or communication to an editor. Following the above notification, a beneficiary may object within fifteen (15) days to the proposed publication or communication. An objection is justified if (a) the protection of the objecting beneficiary's Results or Background would be adversely affected (b) the objecting beneficiary 's legitimate interests in relation to the Results or Background would be significantly harmed (c) the publication contains Confidential Information of the objecting beneficiary. The objection has to include a precise request for necessary modifications. Beneficiaries who fail to answer within fifteen (15) calendar days will be considered to have given their consent. Provided that all reasonable modifications have been implemented, none of the beneficiaries concerned may withhold its consent to publication or communication for a period longer than six (6) months from the date such publication or communication was first notified to the Parties. If an objection has been raised the involved beneficiaries shall discuss how to overcome the justified grounds for the objection in a timely basis (for example by amendment to the planned publication and/or by protecting information before publication) and the objecting beneficiary shall not unreasonably continue the opposition if appropriate measures are taken following the discussion. 8.3.3 Information on EU FUNDING – Obligation and right to use the EU emblem All dissemination connected to the Joint Action must: - display the EU emblem (when displayed in association with another logo, the EU emblem must have appropriate prominence) and - include the following text: “This [insert appropriate description, e.g. report, publication, conference, infrastructure, equipment, insert type of result, etc.] was funded by the European Union’s Health Programme (2014-2020).” All dissemination connected to the Joint Action must stipulate that they arise from the Best-ReMaP Joint Action and include one of the appropriate Joint Action logos in a prominent place. 22 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Publications should also include the following disclaimer: "The content of this [insert appropriate description, e.g. report, publication, conference, etc.] represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.” 8.3.4 Dissemination of another beneficiary’s unpublished Results or Background A beneficiary shall not include in any dissemination activity another beneficiary's Results or Background without obtaining the owning beneficiary 's prior written approval, unless they are already published. The mere absence of an objection is not considered as an approval. 8.3.5 Use of names, logos or trademarks Nothing in this Consortium Agreement shall be construed as conferring rights to use in advertising, publicity or otherwise the name of the beneficiaries or any of their logos or trademarks without their prior written approval. Section 9: Access Rights 9.1 Background included 9.1.1 In Attachment 1, the beneficiaries have identified and agreed on the Background for the Project and have also, where relevant, informed each other that Access to specific Background is subject to legal restrictions or limits. Anything not identified in Attachment 1 shall not be the object of Access Right obligations regarding Background. 9.1.2 Any beneficiary can propose to the Coordinator to modify its Background in Attachment 1. However, approval of the Steering Committee is needed should a beneficiary wish to remove or modify Background in Attachment 1. For avoidance of doubt, under no circumstances should the withdrawal of any Background impair implementation of the Joint Action. 9.2 General Principles 9.2.1 Each beneficiary shall implement its tasks in accordance with the Grant Agreement and shall bear sole responsibility for ensuring that its acts within the Joint Action do not knowingly infringe Third Party property rights. 9.2.2 Any Access Rights granted expressly exclude any rights to sublicense unless expressly stated otherwise. 9.2.3 Access Rights Needed for the performance of the work of a beneficiary under the Joint Action shall be free of any administrative transfer costs. 23 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 9.2.4 Access Rights are granted on a non-exclusive basis. 9.2.5 Results and Background shall be used only for the purposes for which Access Rights to it have been granted. 9.2.6 All requests for Access Rights shall be made in writing. The granting of Access Rights may be made conditional on the acceptance of specific conditions aimed at ensuring that these rights will be used only for the intended purpose and that appropriate confidentiality obligations are in place. 9.2.7 The requesting beneficiary must show that the Access Rights are Needed. 9.3 Access Rights for implementation Access Rights to Results and Background Needed for the performance of the own work of a beneficiary under the Joint Action shall be granted on a royalty-free basis, unless otherwise agreed for Background in Attachment 1. 9.4 Access Rights for Exploitation 9.4.1 Access Rights to Background if Needed for Exploitation of a beneficiary’s own Results, shall be granted on Fair and Reasonable conditions. 9.4.2 Access Rights to Results if Needed for Exploitation of a beneficiary 's own Results shall be granted on Fair and Reasonable conditions. Access rights to Results for internal research activities shall be granted on a royalty-free basis. 9.4.3 A request for Access Rights may be made up to twelve months after the end of the Project or, in the case of Section 9.7.1.2 of this Consortium Agreement after the termination of the requesting beneficiary’s participation in the Joint Action. 9.5 Access Rights for affiliated entities Affiliated entities have Access Rights under the conditions of the Grant Agreement Article 19. Such Access Rights must be requested by the affiliated entity from the beneficiary that holds the Background or Results. Alternatively, the beneficiary granting the Access Rights may individually agree with the beneficiary requesting the Access Rights to have the Access Rights include the right to sublicense to the latter's affiliated entities listed in Article 11.1.1 of the Grant Agreement. Access Rights to affiliated entities shall be granted on Fair and Reasonable conditions and upon written bilateral agreement. Affiliated entities which obtain Access Rights in return fulfil all confidentiality and other obligations accepted by the beneficiaries under the Grant Agreement or this Consortium Agreement as if such affiliated entities were beneficiaries. Access Rights may be refused to affiliated entities if such granting is contrary to the legitimate interests of the beneficiary which owns the Background or the Results. 24 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Access Rights granted to any affiliated entity are subject to the continuation of the Access Rights of the beneficiary to which it is affiliated, and shall automatically terminate upon termination of the Access Rights granted to such beneficiary. Upon cessation of the status as an affiliated entity, any Access Rights granted to such former affiliated entity shall lapse. Further arrangements with affiliated entities may be negotiated in separate agreements. 9.6 Additional Access Rights The Beneficiaries agree to negotiate in good faith any additional Access Rights to Results as might be asked for by any beneficiary, upon adequate financial conditions to be agreed. 9.7 Access Rights for beneficiaries leaving the consortium 9.7.1 Access Rights granted to a beneficiary leaving the consortium 9.7.1.1 Defaulting beneficiary Access Rights granted to a Defaulting beneficiary and such beneficiary's right to request Access Rights shall cease immediately upon receipt by the Defaulting beneficiary of the formal notice of the decision of the Steering Committee to terminate its participation in the consortium. 9.7.1.2 Non-defaulting beneficiary A non-defaulting beneficiary leaving voluntarily and with the other beneficiaries' consent shall have Access Rights to the Results developed until the date of the termination of its participation. It may request Access Rights within the period of time specified in Section 9.4.3. 9.7.2 Access Rights to be granted by any leaving beneficiary Any beneficiary leaving the Joint Action shall continue to grant Access Rights pursuant to the Grant Agreement and this Consortium Agreement as if it had remained a beneficiary for the whole duration of the Joint Action. Section 10: Data protection and data management 10.1 General Data Protection Regulation Each beneficiary will comply with the General Data Protection Regulation (Regulation (EU) 2016/679), hereinafter “GDPR”, and with the national data protection laws where relevant. All used or collected data will be shared in anonymized or pseudonymized format. Each beneficiary stays responsible for the lawfulness of the data in accordance with GDPR and any national data protection laws where relevant, therefore the primary responsibility will stay with the Data Protection Officers of the beneficiaries. 25 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Each beneficiary is aware that anonymization of data is never final and that re-identification is a real risk. Therefore, each beneficiary undertakes to implement technical and legal measures according to the applicable European and National laws to ensure a lawful basis for every data processing and to safeguard the rights of the individuals. 10.2 Informed consent procedures for the collection and storage of personal data Unless otherwise provided, the processing of the personal data is only lawful if the data subject has given consent to the processing for one or more specific purposes. Each beneficiary undertakes to ensure that the data subject is aware of the fact that and the extent to which consent is given. Section 11: Non-disclosure of information 11.1 All information in whatever form or mode of communication, which is disclosed by a beneficiary (the “Disclosing beneficiary”) to any other beneficiary (the “Recipient”) in connection with the Joint Action during its implementation and which has been explicitly marked as “confidential” at the time of disclosure, or when disclosed orally has been identified as confidential at the time of disclosure and has been confirmed and designated in writing within 15 calendar days from oral disclosure at the latest as confidential information by the Disclosing beneficiary, is “Confidential Information”. 11.2 The Recipients hereby undertake in addition and without prejudice to any commitment on non-disclosure under the Grant Agreement, for a period of 5 years after the end of the Project: - not to use Confidential Information otherwise than for the purpose for which it was disclosed; - not to disclose Confidential Information without the prior written consent by the Disclosing beneficiary; - to ensure that internal distribution of Confidential Information by a Recipient shall take place on a strict need-to-know basis; and - to return to the Disclosing Party, or destroy, on request all Confidential Information that has been disclosed to the Recipients including all copies thereof and to delete all information stored in a machine readable form to the extent practically possible. The Recipients may keep a copy to the extent it is required to keep, archive or store such Confidential Information because of compliance with applicable laws and regulations or for the proof of on-going obligations provided that the Recipient comply with the confidentiality obligations herein contained with respect to such copy for as long as the copy is retained. 11.3 The Recipients shall be responsible for the fulfilment of the above obligations on the part of their employees or third parties involved in the Joint Action and shall ensure that they remain so obliged, as far as legally possible, during and after the end of the Joint Action and/or after the termination of the contractual relationship with the employee or third party. 26 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 11.4 The above shall not apply for disclosure or use of Confidential Information, if and in so far as the Recipient can show that: - the Confidential Information becomes publicly available by means other than a breach of the Recipient’s confidentiality obligations; - the Disclosing beneficiary subsequently informs the Recipient that the Confidential Information is no longer confidential; - the Confidential Information is communicated to the Recipient without any obligation of confidentiality by a third party who is to the best knowledge of the Recipient in lawful possession thereof and under no obligation of confidentiality to the Disclosing beneficiary; - the disclosure or communication of the Confidential Information is foreseen by provisions of the Grant Agreement; - the Confidential Information, at any time, was developed by the Recipient completely independently of any such disclosure by the Disclosing beneficiary; or - the Confidential Information was already known to the Recipient prior to disclosure, or - the Recipient is required to disclose the Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, subject to the provision Section 10.7 hereunder. 11.5 The Recipient shall apply the same degree of care with regard to the Confidential Information disclosed within the scope of the Joint Action as with its own confidential and/or proprietary information, but in no case less than reasonable care. 11.6 Each beneficiary shall promptly advise the other beneficiary in writing of any unauthorised disclosure, misappropriation or misuse of Confidential Information after it becomes aware of such unauthorised disclosure, misappropriation or misuse. 11.7 If any beneficiary becomes aware that it will be required, or is likely to be required, to disclose Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, it shall, to the extent it is lawfully able to do so, prior to any such disclosure: - notify the Disclosing beneficiary, and - comply with the Disclosing beneficiary’s reasonable instructions to protect the confidentiality of the information. 27 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 12: Miscellaneous 12.1 Attachments, inconsistencies and severability This Consortium Agreement consists of this core text and Attachment 1 (Background included) Attachment 2 (Accession document) In case the terms of this Consortium Agreement are in conflict with the terms of the Grant Agreement, the terms of the latter shall prevail. In case of conflicts between the attachments and the core text of this Consortium Agreement, the latter shall prevail. Should any provision of this Consortium Agreement become invalid, illegal or unenforceable, it shall not affect the validity of the remaining provisions of this Consortium Agreement. In such a case, the beneficiaries concerned shall be entitled to request that a valid and practicable provision be negotiated which fulfils the purpose of the original provision. 12.2 No representation, partnership or agency Except as otherwise provided in Section 6.4.3, no beneficiary shall be entitled to act or to make legally binding declarations on behalf of any other beneficiary or of the consortium. Nothing in this Consortium Agreement shall be deemed to constitute a joint venture, agency, partnership, interest grouping or any other kind of formal business grouping or entity between the beneficiaries. 12.3 Notices and other communication Any notice to be given under this Consortium Agreement shall be in writing to the addresses and recipients as listed in the most current address list kept by the Coordinator. Formal notices: If it is required in this Consortium Agreement that a formal notice, consent or approval shall be given, such notice shall be signed by an authorised representative of a beneficiary and shall either be served personally or sent by mail with recorded delivery or e-mail or telefax with receipt acknowledgement. Other communication: E-mail (where applicable or necessary with acknowledgement of receipt) fulfils the conditions of written form. Any change of persons or contact details shall be notified promptly by the respective beneficiary to the Coordinator. The address list shall be accessible to all beneficiaries. 28 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 12.4 Assignment and amendments No rights or obligations of the beneficiaries arising from this Consortium Agreement may be assigned or transferred, in whole or in part, to any third party without the other beneficiaries’ prior formal approval. 12.5 Mandatory national law Nothing in this Consortium Agreement shall be deemed to require a beneficiary to breach any mandatory statutory law under which the beneficiary is operating. 12.6 Language This Consortium Agreement is drawn up in English, which language shall govern all documents, notices, meetings, arbitral proceedings and processes relative thereto. 12.7 Applicable law This Consortium Agreement shall be construed in accordance with and governed by the applicable EU law supplemented if necessary by the laws of Belgium excluding its conflict of law provisions. 12.8 Settlement of disputes The beneficiaries shall endeavour to settle their disputes amicably. A dispute between any beneficiaries of the Consortium agreement will be brought into attention of the Steering Committee which will act as a mediator and propose solutions to be agreed by the beneficiaries. The Coordinator will mediate disputes between SC members. Disputes between the Coordinator and any other beneficiary shall primarily be settled through negotiation. Nothing in this Consortium Agreement shall limit the beneficiaries' right to seek injunctive relief in any applicable competent court. Article 41 of the Grant Agreement will be used for unsettled disputes related to the subject-matter referred to in paragraph 2, Article 41 of the Grant Agreement. Section 13: Signatures The beneficiaries have caused this Consortium Agreement to be duly signed by their authorised representatives in as many separate signature pages per beneficiary as there are beneficiaries, the day and year first above written. The beneficiaries agree that digital signatures (with registered digital certificate), and original signatures transmitted via PDF shall be treated as original signatures. 29 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 1. NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ) Signature: Name: Milan Krek, MD, Specialist in Public health Title: Director Date: 30 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 2. BUNDESMINISTERIUM FUER SOZIALES, GESUNDHEIT, PFLEGE UND KONSUMENTENSCHUTZ (BMSGPK) Signature: Name: Katharina Reich Title: Dr. med. univ. Date: 31 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 3. SCIENSANO (SCIENSANO) Signature: Name: Prof. Christian Léonard Title: General manager Date: 32 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 4. MINISTRY OF CIVIL AFFAIRS (MCA) Signature: Name: Mirna Pavlović Title: Assistant Minister Date: 33 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 5. NATSIONALEN CENTAR PO OBSHTESTVENO ZDRAVE I ANALIZI (NCPHA) Signature: Name: Assoc. Prof. Hristo Hinkov, MD, PhD Title: Director Date: 34 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 6. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH) Signature: Name: Asst. Prof. Krunoslav Capak, MD, PhD Title: Director - General Date: 35 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 7. Ministry of Health of the Republic of Cyprus (MoH CY) Signature: Name: Dr. Olga Kalakouta Title: Chief Health Officer Date: 36 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 8. FODEVARESTYRELSEN (DVFA) Signature: Name: Per Preisler Christiansen Title: Deputy Director General (Innovation) Date: 37 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 9. SOTSIAALMINISTEERIUM (MoSA) Signature: Name: Marika Priske Title: Secretary General Date: 38 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 10. TERVEYDEN JA HYVINVOINNIN LAITOS (THL) Signature: Name: Markku Tervahauta Title: Director general Date: 39 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 11. AGENCE NATIONALE DE SECURITE SANITAIRE DE L ALIMENTATION DE L ENVIRONNEMENT ET DU TRAVAIL (ANSES) Signature: Name: Roger GENET Title: Director General Date: 40 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 12. MAX RUBNER INSTITUT BUNDESFORSCHUNGSINSTITUT FUR ERNAEHRUNG UND LEBENSMITTEL (MRI) Signature: Name: Prof. Dr. Pablo Steinberg Title: President Date: 41 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 13. INSTITOUTON YGEIAS TOU PAIDIOU (ICH) Signature: Name: Christina Kanaka-Gantenbein, MD, PhD, FMH (CH) Title: Professor and Chair First Department of Pediatric Medical School, National and Kapodistrian University of Athens Date: 42 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 14. SEMMELWEIS EGYETEM (SU) Signature: Name: Béla Dr. Merkely Title: Rector Date: Signature: Name: Dr. Lívia Pavlik Title: Chancellor Date: Countesigned by: Signature: Name: Irén Baumgartnerné Holló Title: Director General of Economic Management Date: 43 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 15. DEPARTMENT OF HEALTH (DoH) Signature: Name: Dr. Seamus O'Reilly Title: Date: 44 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 16. ISTITUTO SUPERIORE DI SANITA (ISS) Signature: Name: Prof. Silvio Brusaferro Title: President Date: 45 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 17. SLIMIBU PROFILAKSES UN KONTROLES CENTRS (CDPC) Signature: Name: Iveta Gavare Title: Director Date: 46 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 18. LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (LR SAM) Signature: Name: Ieva Gudanaviciene Title: Chief Specialist Date: 47 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 19. Ministry for Health - Government of Malta (MFH) Signature: Name: Joseph Rapa Title: Permanent Secretary Date: 48 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 20. RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (RIVM), and on behalf of the Minister of Health, Welfare and Sport, Signature: Name: Prof. dr. ir. J. Brug Title: Director-General Date: 49 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 21. SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH (SUM) Signature: Name: prof. Tomasz Szczepański Title: Rector of Medical University of Silesia (SUM) Date: 50 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 22. MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (DGS) Signature: Name: Graça Freitas Title: Director-General Date: 51 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 23. INSTITUTUL NATIONAL DE SANATATE PUBLICA (NIPH) Signature: Name: Dr. Radu Cucuiu Title: General Director Date: 52 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Section 13: Signatures AS WITNESS: The beneficiaries have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written. 24. INSTITUT ZA ZASTITU ZDRAVLJA SRBIJEDR MILAN JOVANOVIC BATUT (IPHS) Signature: Name: Verica Jovanovic, MD, MSc, PhD, Associate Professor Title: Acting Director Date: 53 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Attachment 1: Background included Background means any data, know-how or information — whatever its form or nature (tangible or intangible), including any rights such as intellectual property rights — that: (a) is held by the beneficiaries before they acceded to the Agreement, and (b) is needed to implement the action or exploit the results. Because of this need, Access Rights have to be granted in principle, but beneficiaries must identify and agree amongst them on the Background for the Joint Action. This is the purpose of this attachment. BENEFICIARY 11 As to AGENCE NATIONALE DE SECURITE SANITAIRE DE L ALIMENTATION DE L ENVIRONNEMENT ET DU TRAVAIL (ANSES), it is agreed between the beneficiaries that, to the best of their knowledge, The following background is hereby identified and agreed upon for the Joint Action. Specific limitations and/or conditions, shall be as mentioned hereunder: Describe Background Specific limitations and/or Specific limitations and/or conditions for implementation conditions for Exploitation Access is granted to all such For the avoidance of doubt For the avoidance of doubt Background belonging to ANSES does not include ANSES does not include ANSES that is necessary for Background that is: Background that is: ANSES to perform its duties • generated by researchers • generated by researchers as provided for under the not participating in the Action. not participating in the Action. Best-ReMaP Grant Agreement • generated by researchers • generated by researchers only participating in the Action, but participating in the Action, but and for the duration of the in parallel with the Action and in parallel with the Action and Action only. Access to certain outside the scope of the outside the scope of the Background and/or Materials Action. Action. may also be subject to special • subject to any other kind of • subject to any other kind of conditions. intellectual property protection intellectual property protection as well as any current as well as any current applications for such applications for such protection. protection. • Background to which • Background to which ANSES, due to mandatory law ANSES, due to mandatory law and/or any third party rights, is and/or any third party rights, is unable to grant Access rights. unable to grant Access rights. This represents the status at the time of signature of this Consortium Agreement. 54 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 BENEFICIARY 12 As to Max Rubner-Institut, it is agreed between the beneficiaries that, to the best of their knowledge, The following background is hereby identified and agreed upon for the Joint Action. Specific limitations and/or conditions, shall be as mentioned hereunder: Describe Background Specific limitations and/or Specific limitations and/or conditions for implementation conditions for Exploitation Metadata on branded food Implementation on metadata Exploitation on metadata provided evaluated from product monitoring, provided that rights of third parties that rights of third parties are not carried out by the MRI; current are not affected. affected. version: June 2020 No implementation on raw data No exploitation on raw data from from product management. product management. This represents the status at the time of signature of this Consortium Agreement. BENEFICIARY 16 As to ‘ISTITUTO SUPERIORE DI SANITA’, it is agreed between the beneficiaries that, to the best of their knowledge, The following background is hereby identified and agreed upon for the Joint Action. Specific limitations and/or conditions, shall be as mentioned hereunder: Describe Background Specific limitations and/or Specific limitations and/or conditions for implementation conditions for Exploitation Istituto Superiore di Sanità (ISS) Access right to Background is only Access right to Background is only hereby grants Access Rights to granted to the extent that it is granted to the extent that said Background generated by the ISS needed to implement the tasks Background is not subject to terms specific research group directly under the action and conditions in other involved in the Best-ReMaP JA agreements. Access to certain Background and/or Material may be subject to special conditions (MTA, term of use, etc.) This represents the status at the time of signature of this Consortium Agreement. 55 Best-ReMaP JA Consortium Agreement Best-ReMaP JA Consortium Agreement 31st of May 2021 Attachment 2: Accession document ACCESSION of a new beneficiary to Best-ReMaP JA Consortium Agreement, version MAY 2021 [OFFICIAL NAME OF THE NEW BENEFICIARY AS IDENTIFIED IN THE Grant Agreement] hereby consents to become a beneficiary to the Consortium Agreement identified above and accepts all the rights and obligations of a beneficiary starting [date]. NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ) hereby certifies that the consortium has accepted in the meeting held on [date] the accession of [the name of the new beneficiary] to the consortium starting [date]. This Accession document has been done in 2 originals to be duly signed by the undersigned authorised representatives. [Date and Place] [INSERT NAME OF THE NEW BENEFICIARY] Signature(s) Name(s) Title(s) [Date and Place] NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ) Signature(s) Name(s) Title(s) 56 Best-ReMaP JA Consortium Agreement
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel